34 results about "Glucose Metabolic Disorders" patented technology

The invention relates to methods for potentiating, enhancing or restoring glucose responsivity in pancreatic islets or cells. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.

In one aspect, the invention relates to methods for treating a disease or condition associated with abnormal glucose metabolism. In another aspect, the invention relates to a method for reducing incidence or progression of insulin-dependent diabetes mellitus. The methods include orally administering to a mammal in need thereof an effective amount of a composition, which includes a naturally occurring material derived from eggshell, eggshell membrane, or a combination thereof.

The present invention provides a blood glucose system having time synchronization, wherein the blood glucose system (1) for treating a glucose metabolic disorder includes a dosing device (3) having an integrated counter for generating a relative count and a memory for storing dose quantities and counts, a blood glucose measuring device (2) having memory for storing blood glucose measurements and measurement times, and a data processor (4) for processing data from the dosing device (3) and blood glucose measuring device (2) and converting counts to actual times. The data processor synchronizesthe counts with the measurement times using a time standard.

The invention discloses a compound silkworm pupa hypoglycemic health-care medicinal composition as well as a preparation method and application thereof, belonging to the fields of biotechnology and traditional Chinese medicine and pharmacy. The compound silkworm pupa hypoglycemic health-care medicinal composition is innovated specific to the aims of stabilizing and correcting glucose metabolic disorder from the aspect of human body metabolism on the basis of keeping and strengthening original functional factors of silkworm or silkworm chrysalis meal including insect insulin (IGF-1) and 1-deoxynojirimycin (DNJ) and the like by adding essential nutrient factors which are beneficial to anti-oxidation of human bodies, immunoregulation, regulation of blood sugar and the like in a scientific combination way. As proved by experiments, the compound silkworm pupa hypoglycemic health-care medicinal composition disclosed by the invention lowers fasting blood-glucose, enhances the sugar tolerance and remarkably improves the clinical symptoms of a diabetic patient.

Compositions and methods related to ester insulin or derivatives thereof are provided. The compositions include GluA4-ThrB30 ester insulin, in which side chains of GluA4 and ThrB30 of native human insulin or an insulin analogue such as insulin lispro are covalently linked via a single ester bond. The ester insulin is efficiently folded, forming the desired disulfides. The ThrB30-GluA4 ester bond can be cleaved in vitro or in vivo to give the desired folded insulin with full biological activity. The ester insulin is readily prepared by total chemical synthesis, and amendable to cost-effective, large scale manufacturing. Also provided are pharmaceutical compositions and kits for use in practicing the subject methods. Also provided are methods of using the subject compositions and kits in the treatment of a variety of different disease conditions, particularly glucose metabolic disorders such as diabetes and obesity.

The invention discloses a secretion-type FNDC5 protein. The secretion-type FNDC5 protein does not contain a transmembrane domain and can be directly secreted and released into blood; and the amino acid sequence of the FNDC5 protein is SEQ ID NO:1. The secretion-type FNDC5 protein is simple in structure and convenient to obtain. The secretion-type FNDC5 protein can be used for treating obesity-related metabolic disorders; after the secretion-type FNDC5 recombinant protein is injected into the abdominal cavity of a high-fat fed obese mouse model, glucose and insulin tolerance can be effectivelyimproved, and it shows that the protein can obviously relieve glucose metabolic disorders and insulin resistance of obese patients; and fatty liver occurrence can be obviously relieved, the level of plasma cholesterol, free fatty acid and triglyceride is decreased, and it shows that the protein can relieve the lipometabolic disorders of the obese patients. The secretion-type FNDC5 protein can serve as a new drug target for treating the metabolic disease to be developed.

The present invention relates to an oxo indirubin or isoindigo derivative, an oxo aza indirubin or isoindigo derivative, and their optical isomers, racemes, cis / trans isomers and pharmaceutically acceptable salts, which can be used for preparing a drug for treating or preventing diseases such as glucose metabolic disorder, inflammatory or autoimmune disease, neurodegenerative disease, a mental illness, tissue proliferation disease or tumors.